LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Abrir

3.56 9.2

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.24

Máximo

3.6

Indicadores-chave

By Trading Economics

Rendimento

1.9M

-68M

Vendas

-5.8M

42M

Margem de lucro

-163.26

Funcionários

570

EBITDA

25M

-41M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+38.46% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

60M

1.1B

Abertura anterior

-5.64

Fecho anterior

3.56

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de nov. de 2025, 21:34 UTC

Ganhos

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 de nov. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 de nov. de 2025, 23:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 de nov. de 2025, 23:41 UTC

Conversa de Mercado

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 de nov. de 2025, 23:24 UTC

Ganhos

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 de nov. de 2025, 23:24 UTC

Ganhos

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 de nov. de 2025, 23:23 UTC

Ganhos

JBS NV 3Q EPS 52c >JBS

13 de nov. de 2025, 23:23 UTC

Ganhos

JBS NV 3Q Sales $22.6B >JBS

13 de nov. de 2025, 23:04 UTC

Conversa de Mercado

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 de nov. de 2025, 22:02 UTC

Ganhos

Nu Holdings 3Q Net $783M >NU

13 de nov. de 2025, 22:01 UTC

Ganhos

Nu Holdings 3Q Rev $4.2B >NU

13 de nov. de 2025, 21:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 de nov. de 2025, 21:50 UTC

Ganhos

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 de nov. de 2025, 21:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 de nov. de 2025, 21:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 de nov. de 2025, 21:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 de nov. de 2025, 21:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 de nov. de 2025, 21:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 de nov. de 2025, 21:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 de nov. de 2025, 21:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 de nov. de 2025, 21:33 UTC

Conversa de Mercado

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 de nov. de 2025, 21:33 UTC

Ganhos

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 de nov. de 2025, 21:31 UTC

Ganhos

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 de nov. de 2025, 21:25 UTC

Ganhos

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 de nov. de 2025, 21:25 UTC

Ganhos

Figure Tech Solutions 3Q EPS 34c >FIGR

13 de nov. de 2025, 21:23 UTC

Ganhos

Intchains Group 3Q Rev $1.3M >ICG

13 de nov. de 2025, 21:03 UTC

Ganhos

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 de nov. de 2025, 21:02 UTC

Ganhos

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 de nov. de 2025, 21:01 UTC

Ganhos

Applied Materials 4Q Rev $6.8B >AMAT

13 de nov. de 2025, 21:01 UTC

Ganhos

Applied Materials 4Q Gross Margin 48.0% >AMAT

Comparação entre Pares

Variação de preço

Maravai LifeSciences Holdings Inc (Class A) Previsão

Preço-alvo

By TipRanks

38.46% parte superior

Previsão para 12 meses

Média 4.5 USD  38.46%

Máximo 5 USD

Mínimo 4 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Maravai LifeSciences Holdings Inc (Class A) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

3

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.02 / 2.115Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

No Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat